C-Myc-activated long non-coding RNA LINC01050 promotes gastric cancer growth and metastasis by sponging miR-7161-3p to regulate SPZ1 expression

Abstract

Background Growing evidence shows that long non-coding RNAs (lncRNAs) play significant roles in cancer development. However, the functions of most lncRNAs in human gastric cancer are still not fully understood. Here, we explored the role of a novel c-Myc-activated lncRNA, LINC01050, in gastric cancer progression. Methods The expression of LINC01050 in the context of gastric cancer was assessed using The Cancer Genome Atlas datasets. Its functions in gastric cancer were investigated through gain- and loss-of-function experiments combined with the Cell Counting Kit-8 assays, colony-forming assays, Transwell assays, flow cytometry, Western blot analyses, and xenograft tumor and mouse metastasis models. Potential LINC01050 transcription activators were screened via bioinformatics and validated by chromatin immunoprecipitation and luciferase assays. The interaction between LINC01050 and miR-7161-3p and the targets of miR-7161-3p were predicted by bioinformatics analysis and confirmed by a luciferase assay, RNA immunoprecipitation, RNA pull-down, and rescue experiments. Results LINC01050 was significantly up-regulated in gastric cancer, and its high expression was positively correlated with a poor prognosis. The transcription factor c-Myc was found to directly bind to the LINC01050 promoter region and activate its transcription. Furthermore, overexpression of LINC01050 was confirmed to promote gastric cancer cell proliferation, migration, invasion, and epithelial-mesenchymal transition in vitro and tumor growth in vivo. At the same time, its knockdown inhibited gastric cancer cell proliferation, migration, invasion, and epithelial-mesenchymal transition in vitro along with tumor growth and metastasis in vivo. Moreover, mechanistic investigations revealed that LINC01050 functions as a molecular sponge to absorb cytosolic miR-7161-3p, which reduces the miR-7161-3p-mediated translational repression of SPZ1, thus contributing to gastric cancer progression. Conclusions Taken together, our results identified a novel gastric cancer-associated lncRNA, LINC01050, which is activated by c-Myc. LINC01050 may be considered a potential therapeutic target for gastric cancer.

LINC01232 Promotes Metastasis and EMT by Regulating miR-506-5p/PAK1 Axis in Gastric Cancer

“… 24 In gastric cancer cells, LINC01050 is activated by c-Myc and facilitate metastasis by sponging miR-7161-3p to upregulate SPZ1. 25 LncRNA SLCO4A1-AS1 accelerates metastasis of gastric cancer through modulating the miR-149/XIAP axis. 26 RNF144A-AS1 promotes metastasis in gastric cancer by targeting the miR-30c-2-3p/LOX axis.…”

Epithelial-mesenchymal transition-related long noncoding RNAs in gastric carcinoma

“…LncASNR (apoptosis suppressing-non-coding RNA) inhibits the expression of miR-519e-5p but up-regulates fibroblast growth factor receptor 2 (FGFR2). As a receptor for FGF, FGFR2 can deliver the FGF signal to RAS-ERK and PI3K-AKT signal cascades, facilitating EMT-related migration and invasion of GC cells (Chen Z. et al, 2021). Overexpression of lncRNA HLA complex group 18 (HCG18) induced by hepatocyte nuclear factor 1 homeobox A (HNF1A) promotes GC progression by competitively binding to miR-152-3p and upregulating DNAJB12.…”

Pan-cancer analysis of super enhancer-induced PRR7-AS1 as a potential prognostic and immunological biomarker

“…LncRNA is implicated in numerous vital regulatory functions including cell cycle regulation, genomic imprinting, gene reprogramming, chromatin modification, transcriptional activation, and intranuclear transport, as well as the development and prevention of human diseases ( Wang et al, 2011 ; Iyer et al, 2015 ). It has been demonstrated in many studies that lncRNA expression disorders are associated with a variety of cancers and these frequent aberrant expressions are closely related to tumorigenesis, development and metastasis ( Ji et al, 2021 ; Feng et al, 2022 ). Related researches also find that lncRNA regulates drug resistance in multiple tumor types on top of its oncogenic function ( Barik et al, 2021 ; Zhou L. et al, 2022 ; Zhou Y. et al, 2022 ).…”